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ABSTRACT By following a strategy of genetic analysis of
poliovirus, we have constructed a synthetic "mutagenesis
cartridge" spanning the genome-linked viral protein coding
region and flanking cleavage sites in an infectious cDNA clone
of the type 1 (Mahoney) genome. The insertion of new
restriction sites within the infectious clone has allowed us to
replace the wild-type sequences with short complementary
pairs of synthetic oligonucleotides containing various muta-
tions. A set of mutations have been made that create methio-
nine codons within the genome-linked viral protein region.
The resulting viruses have growth characteristics similar to
wild type. Experiments that led to an alteration of the tyrosine
residue responsible for the linkage to RNA have resulted in
nonviable virus. In one mutant, proteolytic processing assayed
in vitro appeared unimpaired by the mutation. We suggest that
the position of the tyrosine residue is important for genome-
linked viral protein function(s).
Poliovirus, like all members of the picornavirus family, has a
messenger-sense, single-stranded RNA genome. The viral
RNA is 7441 nucleotides long exclusive of the genetically
encoded polyadenylate tract at the 3' terminus (1). Its
sequence is known (2, 3) as are the genetic loci and amino
acid sequences of all virus-encoded polypeptides (2). The 5'
terminus of viral RNA is blocked by a genome-linked viral
protein, VPg (4, 5). VPg is a small (22 amino acid), basic
protein that is covalently linked to the polynucleotide chain
through a phosphodiester bond between the 5'-terminal
uridine residue and the 04 of the tyrosine residue (6, 7). All
virus-induced RNAs found in the infected cell, with the
exception ofmRNA, contain VPg at their 5' ends (8-10). The
release of VPg from mRNA is accomplished by a cellular
protein termed the unlinking enzyme that leaves a pU at the
5' end of the RNA (11). Though the function(s) of VPg is
unknown, it has been suggested that it may serve as a primer
for the primer-dependent RNA polymerase (8). Indeed,
following uridylylation of VPg in vitro, the product VPg-
pUpU can be elongated into longer RNA polynucleotide
chains, a result in support of the primer model for VPg
function (12, 13). VPg has also been proposed (ref. 14 and
references cited therein) to function as a nuclease, cleaving
the hairpin of end-linked double-stranded RNA. It, there-
fore, seems likely that, despite its small size, VPg may play
an integral role in the replication of the virus.
The ability to construct mutations in an infectious cDNA
copy of the poliovirus genome and to recover viable viral
mutants has been demonstrated (15-19). Such mutants can
prove invaluable in deciphering the function of a particular
polypeptide or region of the viral genome. The difficulty
remains in determining the target site for mutation. Those
procedures that are useful for generating a series of muta-
tions in a given DNA sequence, although thorough, usually
contain an inherent bias as to the location (insertion/deletion
mutants) or to the nature of the nucleotide change (20).
However, site-directed oligonucleotide mutagenesis allows
one to precisely change nucleotides at will with no bias,
though one is limited in the number of changes per oligonu-
cleotide used to generate mismatches. The small size of VPg
(22 amino acids), its unusual amino acid composition, and
the availability of other picornavirus VPg sequences for
homology determinations identified it as an excellent target
for extensive site-directed mutagenesis experiments and
afforded us an opportunity to examine in detail the amino
acid requirements for VPg function(s).
By using infectious cDNA clones (21, 22) and an in vitro
transcription system to generate highly infectious viral RNA
(29), we have constructed a "mutagenesis cartridge" span-
ning the VPg coding region and flanking proteolytic cleavage
sites. The creation of unique restriction sites in the region of
the genome coding for VPg coupled with the insertion of
synthetic mutant oligonucleotides permits a quick and ex-
tensive mutational analysis of the region. This cartridge has
been used to investigate the role of the tyrosine residue that
links VPg with the RNA. In addition, mutants have been
made that create one or more methionine codons within the
VPg sequence, allowing for direct labeling of VPg with
[35S]methionine. Our results suggest that specific amino acid
substitutions in VPg differentially affect the covalent attach-
ment of this protein to RNA and its cleavage from precursor
polypeptides.
MATERIALS AND METHODS
Cells and Viruses. All virus propagation and plaque assays
were performed on HeLa cell monolayers maintained in
Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% (vol/vol) fetal bovine serum. Wild-type
poliovirus used for experiments was a plaque-purified isolate
derived following a transfection of COS-1 cells with pEV104
(22). Viral RNA was isolated and sequenced essentially as
described by Pincus et al. (23). The primer used for sequenc-
ing DNA and RNA is complementary to nucleotides (nt)
5449-5463 of the plus-strand viral RNA. The nomenclature
of viral mutants follows the suggestion of Bernstein et al.
(17): name of the laboratory head (W), serotype of poliovirus
(1), location of the mutated gene segment (VPg), and number
of mutant.
Construction of Synthetic Cartridge. Oligonucleotides
were synthesized on a Systec 1450 using phosphoramidite
Abbreviations: VPg, genome-linked viral protein; nt, nucleotide(s).
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chemistry. The BstEII and Ava I restriction sites were
inserted into the polio cDNA sequence by using an
M13mplO derivative grown in Escherichia coli strain BW313
(24) and oligonucleotide-directed mutagenesis essentially as
described by Zoller and Smith (25). The synthetic cartridge
was assembled by annealing six complementary oligonucle-
otides followed by stepwise ligations. The final product was
purified by elution from an 8% acrylamide gel and was used
to construct pNT15 (Fig. 1). The sequence of the cartridge
was confirmed by a modified dideoxy chain-termination
procedure (27, 28).
Transcriptions and Transfections. The fragment of DNA
containing the desired mutation(s) was inserted into the T7
RNA transcription plasmid pT7PV1-5 (29). Template was
prepared and transcription was performed as described (29).
In vitro translations were carried out as described by Ypma-
Wong and Semler (30). Infected virus extracts added to the
translations are from a poliovirus-infected HeLa cell S10
fraction (30).
RNA transfections were carried out in T25 flasks (106
HeLa cells per flask) and were performed essentially as
described by van der Werf et al. (29).
RESULTS
Construction of pT7-VPgl5. To probe the function(s) of the
genome-linked protein, we constructed a synthetic mutagen-
esis cartridge for the replacement of short sequences of
DNA by using new restriction sites inserted into the VPg
region of the polio genome. The initial step in the construc-
tion of this cartridge was the introduction of two unique
restriction sites flanking the VPg coding region. The two
sites were chosen such that the primary structure of the
polyprotein would be unaltered and that the entire coding
sequence for VPg and the flanking cleavage sites would be
contained within it (Fig. 2).
The BstEII restriction site at nt 5362 and the Ava I
restriction site at nt 5440 were created independently by
oligonucleotide-directed mutagenesis using an M13mplO-
derived vector as shown in Fig. 1. The appropriate mutant
oligonucleotide (15 nt long with one mismatch), along with
w.
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FIG. 2. Schematic of the VPg mutagenesis cartridge and VPg
mutants. The limits of the cartridge are defined at the 5' end by the
BstEII site and at the 3' end by the Ava I site. The hatched box
represents the primary sequence of VPg, with the one-letter amino
acid code for the wild type (WT) (type 1, Mahoney) shown under-
neath. This sequence differs from the pT7-VPgl5 sequence at
position 10, in which arginine of pT7-VPgl5 replaces the wild-type
lysine. This change is present in all mutants generated with the
cartridge. The other mutants are shown with their respective alter-
ations replacing the dashed line. The * denotes a mutation that was
not made by using the cartridge.
the M13 sequencing primer, was annealed to a template that
had been prepared from a Dut -Ung E. coli strain (24). The
primers were extended with the large fragment of DNA
polymerase I (Klenow) and ligated with T4 DNA ligase,
followed by digestion with HindIII to remove the polio
cDNA fragment. The polio cDNA fragment was then in-
serted into the HindIII restriction site ofpNT4 (22). Recom-
binant clones were screened for the presence of the mutation
by digestion with the appropriate restriction enzyme.
The synthetic mutagenesis cartridge was assembled by the
ligation of the Stu I-Ava II oligonucleotide pair to the Ava
II-Ava I oligonucleotide pair. The ligation mixture was
electrophoresed on a preparative polyacrylamide gel, and
the correct fragment was excised, eluted from the gel, and
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FIG. 1. Strategy for the construc-
tion of plasmid pNT15. Polio cDNA
sequences are denoted by the solid
line. The plasmid pIN-III-C3-7c was
used as a convenient donor for the
polio sequences required for VPg mu-
tagenesis (26). M13mp1O was linear-
ized by digestion with HindIll. The
polio-specific HindIII fragment of
pIN-III-C3-7c was ligated to the M13
vector generating M13-RK04. The
hatched box represents the synthetic
mutagenesis cartridge. The origin of
plasmid pNT4 is given in ref. 22.
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ligated to the BstEII-Stu I oligonucleotide pair. The result-
ing 78-base-pair fragment was again purified by gel electro-
phoresis. Once assembled, the synthetic cartridge was li-
gated to DNA fragments from pNT5 and pNT6 to generate
pNT15 (Fig. 1). This plasmid contains the functional muta-
genesis cartridge: five new restriction sites have been in-
serted (BstEII, Stu I, Ava II, Ava I, and Sma I) and one site
has been removed (Ava II). With the exception of one amino
acid, which will be discussed below, the primary sequence of
the wild-type polyprotein has been maintained, although the
nucleotide sequence has been altered in eight positions.
Dideoxy sequencing was performed directly on the double-
strand plasmid DNA to confirm the sequence of the muta-
genesis cartridge. Following this step, a Bgl IlBgl II diges-
tion was performed, and the resulting 283-base-pair fragment
(nt 5318 to nt 5601) was used to replace the corresponding
wild-type fragment from pT7PV1-5. The plasmid, designated
pT7-VPgl5, which was recovered, was sequenced starting
from nt 5449 and proceeding through the Bgl I site at nt 5318
to confirm its identity. Two independent clones were iso-
lated from each mutant to ensure the mutation created was
responsible for the phenotype.
Isolation of Poliovirus Mutant W1-VPgl5. Following large-
scale purification of plasmid pT7-VPgl5, the plasmid was
prepared for transcription by T7 RNA polymerase by linear-
ization at the unique EcoRI site immediately on the 3' side of
the poly(A) tract of the polio cDNA (29). The transcription
reaction was performed as described above, and the result-
ing RNA transcripts were used in transfections of HeLa cell
monolayers. Eighteen to twenty-four hours after transfec-
tion cytopathic effects were observed. Following total cell
lysis, W1-VPgl5, the virus recovered, was added to HeLa
cell monolayers to generate a stock of virus. To verify the
altered genomic sequence of the virus, genomic RNA was
purified, and the nucleotide sequence of the VPg region was
determined directly by chain-termination sequencing. The
sequence of the viral RNA was found to be identical to that
of the mutagenesis cartridge.
As was mentioned, the amino acid sequence of the muta-
genesis cartridge was not completely identical to the type 1
(Mahoney) sequence. The lysine residue at position 10 of
VPg had been replaced by an arginine residue. This alter-
ation was necessitated by the placement of the unique Stu I
restriction site in the center of the mutagenesis cartridge.
The possibility that this amino acid substitution would affect
VPg function and virus growth was quite low, because (i)
this was a conservative change that maintains the charge at
the normal position and (it) both the type 2 (Lansing) and the
type 3 (Leon) strains of poliovirus have an arginine in place
of the lysine found in type 1 (31, 32).
The titer of W1-VPg15 was determined in parallel with
wild-type virus at 33.5°, 37.00, and 39.5°C. At all three
temperatures both viruses produced titers that were within
0.5 log1o unit of each other. A one-step growth experiment
was carried out to determine the replication efficiency of
W1-VPg15 (data not shown). The growth rate for W1-VPgl5
was found to be indistinguishable from the wild-type control
virus.
VPg Mutants Containing Methionine Residues. The eluci-
dation of the role VPg plays in RNA synthesis has been
hampered by the difficulty in detecting free VPg or small
nucleotide-protein complexes, the latter being visualized
only after incorporation of [a-32P]UTP in vitro (12, 13).
Though a precursor of VPg, 3AB, can be followed after
[35S]methionine labeling, nucleotides have never been found
attached to it. To simplify the study ofVPg and its function(s),
a methionine codon was inserted into the VPg coding region.
The amino acid sequence of the VPg from the enterovirus
echovirus 9 is highly conserved compared to poliovirus VPg,
differing in only one position through the first 11 amino acids
(33). This difference occurs at amino acid position 6, where
poliovirus has a leucine and echovirus 9 has a methionine.
Based on this homology and the conservative nature of the
change, a methionine codon was introduced into the synthetic
cartridge at position 6 ofVPg (Fig. 2). This cartridge was then
inserted into the full-length clone generating pT7-VPg22.
Following transfection of HeLa cells with RNA described
from pT7-VPg22, infectious virus was recovered and desig-
nated W1-VPg22. This virus was shown by dideoxy sequenc-
ing to contain the methionine codon.
Another mutant containing a methionine codon in the VPg
region was fortuitously discovered while sequencing pNT15
clones and contains a methionine in place of a valine at
position 13 of VPg (Fig. 2). During either the synthesis of the
oligonucleotide or the cloning, an adenosine residue substi-
tuted for the wild-type guanosine residue, and an AUG
codon was generated. This mutant when placed into the
full-length clone also yielded a viable virus with the correct
sequence and was designated W1-VPg3O. Since this mutant
mapped downstream of the Stu I restriction site and the
methionine codon from pT7-VPg22 mapped upstream of the
site, it was possible to combine the two mutations in a single
step. Such a recombinant was made, and it too produced
infectious virus after transfection. The recovered virus con-
tains two methionine residues in the VPg polypeptide and
was designated W1-VPg31 (Fig. 2).
The three viruses with the methionine substitutions in VPg
were examined to determine whether these mutations im-
parted any deficiencies on the resultant viruses. Plaque
titrations at 33.5°, 37.00, and 39.5°C showed the normal
variation as did wild type (data not shown). The one-step
growth curves for these viruses indicated that they grow as
well as the original mutant W1-VPgl5 and the wild-type
virus (data not shown). To determine whether the processing
of viral proteins in the mutant viruses has been altered,
infected cells were pulse-labeled with [35S]methionine 3 hr
after infection. The pattern of viral proteins produced in
each mutant is similar to that produced from the wild-type
control (Fig. 3A). There appears to be less-effective inhibi-
tion of host-cell protein synthesis in some of the lanes, the
significance of which is uncertain. When a higher multiplic-
ity of infection was used, host-cell shut-off was normal. The
immunoprecipitations (Fig. 3B) demonstrate that, in each
mutant virus, the altered VPg polypeptide and its precursors
can be recognized by the appropriate antisera. Although not
included in Fig. 3B, W1-VPg31 also shows the same pattern
of immunoprecipitated products present in the other mu-
tants. Note that VPg can be seen in those cases where it
contains a methionine residue. This data confirms that free
VPg exists in the infected cells (35).
VPg of echovirus 9 differs only in 4 amino acids from
poliovirus VPg (Met-6, Lys-12, Leu-16, and Gln-18; ref. 33).
We have changed the corresponding amino acids in W1-
VPg15 to those of echovirus 9 VPg and obtained a mutant
virus (W1-VPg29) that was viable at 32°C and at 37°C and
yielded plaques indistinguishable in size from those obtained
with W1-VPgl5. The results of this experiment demonstrate
that an allele replacement in the region of VPg between two
human enteroviruses is compatible with viral replication.
Mutagenesis of the Tyrosine Residue. The tyrosine residue
at position 3 in VPg is responsible for the linkage of VPg to
the RNA. A comparison of the amino acid sequence of 27
picornaviral VPgs indicates an invariance for the tyrosine
residue at position 3. To examine more closely the role of the
tyrosine residue in VPg, two mutations were constructed.
The first mutation, created by oligonucleotide site-directed
mutagenesis in M13 prior to the construction of the synthetic
mutagenesis cartridge, inserts a tyrosine reside in place of
the threonine residue at position 4 (pT7-VPg21). This gener-
ates a VPg molecule that contains two tyrosines adjacent to
Genetics: Kuhn et al.
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each other and preserves the original position of the tyrosine
residue. Because it is not a derivative of pNT15, it contains
only the threonine -+ tyrosine change at position 4 and not
the lysine -* arginine change at position 10. The second
mutation removes the tyrosine from the conserved third
position and inverts it with respect to the threonine at
position 4, generating a molecule having a tyrosine at posi-
tion 4 and a threonine at position 3 (pT7-VPg16).
Both of these mutants described above failed to produce
virus under the RNA transfection assay conditions. Cells
had been transfected with the mutant RNAs at 33.5°, 37.00,
or 39.5°C, either under agar or under liquid medium, how-
ever, infectious virus was never recovered. To determine
whether this result was due to an intrinsic defect in the
functioning of VPg or whether it might be the result of a
conformational change affecting the cleavage site and alter-
ing or preventing the cleavage by proteinase 3CP'°, RNA
was transcribed by T7 polymerase in vitro. This was fol-
lowed by in vitro translation of the RNA under conditions
that allow optimal proteolytic processing (30). The results of
this experiment (Fig. 4) show that the proteinase 3CP"' is
capable of processing the glutamine/glycine cleavage sites
defining VPg for pT7-VPgl6 but not for pT7-VPg21. The
translation products of wild-type viral RNA, pT7PV1-5,
pT7-VPgl5, and pT7-VPgl6 RNA are completely identical
with or without the addition of an infected viral extract.
Therefore, the data suggest that the lesion introduced by
modification of the tyrosine residue in pT7-VPgl6 acts
directly on the function of VPg and does not inhibit proteo-
lytic processing.
The situation for pT7-VPg21 appears to be more complex.
Processing of the polyprotein is reduced in this mutant as
evidenced by a decrease in the appearance of the capsid
polypeptides VPO and VP1. More dramatic is the decrease in
the P3 polypeptides, even after immunoprecipitation (data
not shown), which suggests the block to virus production
may lie in the inability of the proteinase to process the
glutamine/glycine cleavage site separating protein 3A and
swab
FIG. 3. (A) [35S]Methionine labeling of
HeLa cells infected with wild-type poliovirus
and the VPg mutants at multiplicity of infection
of 25. Labeling was performed from 3 to 5 hr
after infection, at which time lysates were pre-
pared and electrophoresed on a 12.5% NaDod-
S04/polyacrylamide gel. (B) Lysates were pre-
pared as described in A except cells were
infected at a multiplicity of infection of 100.
Lysates were subjected to immunoprecipitation
with anti-VPg (N10+ C7) sera (12, 34) and anti-
3A serum and electrophoresed. The rabbit anti-
3A serum was induced with a carrier-linked
synthetic decapeptide corresponding to the N-
terminal sequence of polypeptide 3A (R.J.K.,
T. Takegami, and E.W., unpublished results)
and specifically recognizes 3A and its precur-
sors. Like anti-VPg sera, anti-3A nonspecifi-
cally precipitates capsid proteins. WT, wild
type; M, marker.
VPg. However, it is not known whether the uncleaved
precursor of VPg can be uridylylated in vivo. An additional
protein band appears that migrates faster than band 3CD
(:70 kD) and is not present in the other lanes. This poly-
peptide can be immunoprecipitated by anti-2A, -2C, -3A,
and -VPg (but not by anti-3C) antibodies and may be
polypeptide P2-3AB (36). The addition of an infected virus
extract containing proteinase activity to the translation mix
of pT7-VPg21 results in further processing of the capsid
proteins to levels that are seen in the wild-type control,
whereas the level of 3CD is unaffected by the addition of
exogenous viral proteins.
DISCUSSION
We have followed a strategy of genetic analysis of poliovirus
by constructing a mutagenesis cartridge spanning the region
of the poliovirus genome encoding VPg and its flanking
cleavage sites. This cartridge was designed to be easily
accessible to manipulation and to contain sufficient restric-
tion sites such that oligonucleotide synthesis would be kept
to a minimum. This approach has allowed us to perform a
genetic analysis of this polypeptide with the objective of
determining its function(s) and exploring how the primary
and secondary structures of VPg carry them out. The data
presented here indicate that mutations can be introduced
into VPg with either little or no effect on the resulting virus
or that they can result in a complete inactivation of the virus.
It is assumed that intermediates, that is, conditional-lethal
mutants mapping in VPg, will also be isolated.
The mutant viruses that were designed to have methionine
within the amino acid sequence ofVPg allowed us to label VPg
with [35S]methionine. This facilitates the study of the metabo-
lism ofVPg in vivo and in vitro. Moreover, we have exchanged
VPg of poliovirus with that of echovirus 9 with little effect on
virus growth. Thus, a number of residues in poliovirus VPg
appear to have spacer function and are replaceable.
The mutation in plasmid pT7-VPgl6 that was directed at
altering the position of the linkage amino acid and the
522 Genetics: Kuhn et al.
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FIG. 4. In vitro translation of T7-transcribed RNA from
pT7PV1-5, pT7-VPglS, pT7-VPgl6, and pT7-VPg21. Translations
were performed as described (30). Following translations an infected
viral extract, competent for proteolytic processing, was added to the
mixtures as indicated and incubated at 300C for 60 min. The
products were then electrophoresed on a 10% NaDodSO4/polyacryl-
amide gel and visualized by fluorography. VRNA, viral RNA.
Absence (-) or presence (+) of infected cell extract is indicated.
mutation in plasmid pT7-VPg21 that altered the target for the
linking enzyme failed to produce infectious virus. In the
latter case, where a tyrosine was substituted for a threonine
directly adjacent to the linkage tyrosine, the protein pro-
cessing pattern, as assayed by in vitro translation of the
T7-transcribed RNA, shows a dramatic alteration in the P3
region of the polyprotein. This aberrant processing may
itself be the primary block to virus replication since the
3A/3B-glutamine/glycine cleavage site no longer appears to
be a substrate for the viral proteinase or the block may be
coupled to an inability to link RNA to this mutated polypep-
tide. Since processing of the capsid precursors can proceed
normally after the addition of an infected extract, whereas
certain P3 precursors are unaffected by the addition, it is
likely the insertion of the tyrosine residue disturbs the
folding of the polyprotein on its carboxyl-terminal side. Such
a misfolding may account for the reduced level of processing
and the inhibition of exogenously added proteinase to cleave
the P3 region polypeptides.
The mutation affecting the position of the tyrosine, pT7-
VPg16, can be interpreted more precisely. Since the pro-
cessing of the polyprotein is unaffected by the amino acid
alteration, the defect lies in VPg function. Every picornavirus
VPg sequenced to date has the tyrosine residue at position 3
conserved whereas those amino acids surrounding the tyro-
sine residue are quite variable. We suggest that the position of
the tyrosine may be more important for VPg function than the
immediately surrounding amino acid context.
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